Compare · ACHV vs QTNT

ACHV vs QTNT

Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Quotient Limited (QTNT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ACHV and QTNT operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • ACHV carries a market cap of $697.7M.
  • ACHV has hit the wire 5 times in the past 4 weeks while QTNT has been quiet.
  • ACHV has more recent analyst coverage (11 ratings vs 2 for QTNT).
MetricACHVQTNT
Company
Achieve Life Sciences Inc.
Quotient Limited
Price
-
-
Market cap
$697.7M
-
1M return
-8.17%
-
1Y return
+54.90%
-
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
2014
News (4w)
5
0
Recent ratings
11
2
ACHV

Achieve Life Sciences Inc.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

QTNT

Quotient Limited

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ COVID-19 Microarray that is designed as a serological disease screening microarray specific to COVID-19 antibody detection. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.